机译:鉴别吡咯并[2,3-D]嘧啶的衍生物作为有效和口服有效的FMS酪氨酸受体激酶3(FLT3)抑制剂,用于治疗急性髓性白血病
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Sichuan Univ West China Hosp Dept Hematol Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Sichuan Univ West China Hosp Dept Hematol Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
Natl Clin Res Ctr Geriatr State Key Lab Biotherapy &
Canc Ctr Chengdu 610041 Sichuan Peoples R China;
机译:鉴别吡咯并[2,3-D]嘧啶的衍生物作为有效和口服有效的FMS酪氨酸受体激酶3(FLT3)抑制剂,用于治疗急性髓性白血病
机译:设计,合成和评估新型的双重fms样酪氨酸激酶3 /干细胞因子受体(FLT3 / c-KIT)抑制剂,用于治疗急性粒细胞性白血病
机译:发现有效和口服有效的双janus激酶2 / flt3抑制剂,用于治疗急性髓性白血病和myeloproiferative肿瘤(Vol 62,Pg 10305,2019)
机译:以喹唑啉作为一般支持物来设计有效和选择性激酶抑制剂:在类似FMS的酪氨酸激酶3中的应用
机译:ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
机译:患有急性髓样白血病和高危骨髓增生异常综合症(无论是野生型还是突变型FLT3)的患者口服Midostaurin(PKC412)FMS类酪氨酸激酶3受体(FLT3)和多靶点激酶抑制剂IIB期临床试验
机译:吡咯的鉴定基于嘧啶的衍生物作为有效和口服有效的FMS样酪氨酸受体激酶3(FLT3)抑制剂,用于治疗急性髓性白血病